RSV: On the verge of change
After decades of failed attempts, the respiratory syncytial virus (RSV) treatment and vaccine landscape is on the verge of profound change.
Several pharmaceutical companies have an RSV vaccine or preventative treatment in late-stage clinical trials – demonstrating highly promising results – and are racing to become the first to market.
In this short article, we highlight some of the key developments in this area, potential knowledge gaps and considerations for the future.
Download
